1. Introduction {#sec1-pathogens-06-00018}
===============

Enterotoxigenic *Escherichia coli* (ETEC) causes travelers' diarrhea and diarrheal disease in children living in developing countries \[[@B1-pathogens-06-00018],[@B2-pathogens-06-00018]\]. ETEC strains encode two main types of virulence factors---heat-labile and/or heat-stable toxins (LT and ST)---that cause watery diarrhea \[[@B3-pathogens-06-00018]\] and colonization factors (CFs) that mediate ETEC adherence to intestinal enterocytes \[[@B4-pathogens-06-00018]\]. In addition to causing diarrhea, LT enhances ETEC adherence to host cells by activating host signaling pathways, and inhibits antimicrobial peptide and cytokine (e.g., IL-8) production by disrupting nuclear factor-κB (NF-κB) signaling pathway activation \[[@B5-pathogens-06-00018]\].

Flagella play critical roles in ETEC virulence \[[@B6-pathogens-06-00018]\]. For example, in addition to their role in bacterial motility, flagella promote ETEC attachment to intestinal epithelial cells \[[@B7-pathogens-06-00018]\] and affect biofilm formation \[[@B8-pathogens-06-00018]\]. EtpA, an exoprotein adhesin, mediates ETEC adhesion between flagella and host cells \[[@B9-pathogens-06-00018]\].

NF-κB plays an important role in regulating inflammation and innate immune responses to microbial infections \[[@B10-pathogens-06-00018]\]. NF-κB is normally sequestered in the cytoplasm by the NF-κB inhibitor, IκBα. Upon TNF stimulation or microbial infection, the IκB kinase (IKK) complex is activated and phosphorylates IκBα which is then polyubiquitinated and degraded, resulting in nuclear translocation of NF-κB subunits \[[@B11-pathogens-06-00018]\]. The innate immune system recognizes pathogens through a diverse set of cellular pattern recognition receptors \[[@B12-pathogens-06-00018]\]. Pathogens have accordingly evolved mechanisms to subvert innate signaling pathways to promote their survival and transmission \[[@B13-pathogens-06-00018]\].

We previously reported that pre-incubation of HCT-8 cells with ETEC H10407 supernatant prevented TNF stimulation from inducing IκBα degradation and NF-κB activation \[[@B14-pathogens-06-00018]\]. We attributed this result to a heat-stable protein we designated as ETEC Secreted Factor (ESF). Here we fractionated ETEC supernatants and identified flagellin as necessary and sufficient for this phenomenon.

2. Results and Discussion {#sec2-pathogens-06-00018}
=========================

2.1. ETEC H10407 Secretes ESF into M9 Minimal Media {#sec2dot1-pathogens-06-00018}
---------------------------------------------------

We previously found that ETEC H10407 secretes a heat-stable protein (ETEC Secreted Factor or ESF) into RPMI 1640 medium that subsequently inhibits the ability of TNF to activate NF-κB signaling \[[@B14-pathogens-06-00018]\]. To facilitate identification of this protein using biochemical fractionation, we first determined whether this factor was also secreted into the ETEC supernatant when ETEC was grown in M9 minimal medium. We incubated HCT-8 cells with either cell-free ETEC-M9 or ETEC-RPMI 1640 supernatants for 1.5 h and then treated the cells with TNFα (20 ng/mL, 20 min). Pre-incubating HCT-8 cells with ETEC-M9 supernatant significantly inhibited IκBα degradation in response to TNFα stimulation ([Figure 1](#pathogens-06-00018-f001){ref-type="fig"}A), similar to the results obtained from pretreating HCT-8 cells with ETEC-RPMI 1640 supernatant ([Figure 1](#pathogens-06-00018-f001){ref-type="fig"}B; \[[@B14-pathogens-06-00018]\]). IκBα degradation was not observed in cells pre-incubated with only ETEC-RPMI 1640 or ETEC-M9 supernatants in the absence of TNF ([Figure 1](#pathogens-06-00018-f001){ref-type="fig"}C). These data indicated that ETEC H10407 also secretes the ESF into M9 minimal medium.

Next, we used FPLC to fractionate ETEC-M9 supernatants and then assayed the fractions for their ability to block TNF-induced NF-κB activation. Two fractions ([Figure 1](#pathogens-06-00018-f001){ref-type="fig"}D, fractions E and F) inhibited IκBα degradation in HCT-8 cells and silver staining data showed that these two fractions had a similar protein composition ([Figure 1](#pathogens-06-00018-f001){ref-type="fig"}E). We excised these bands and identified the proteins using mass spectrometry ([Table 1](#pathogens-06-00018-t001){ref-type="table"}). We identified a major outer membrane lipoprotein, outer membrane protein A, the flagellar hook-associated protein FliD, and flagellin (FliC). *E. coli* K-12 strains do not encode the ESF \[[@B14-pathogens-06-00018]\]. The two outer membrane proteins are highly conserved between ETEC and *E. coli* K-12, but FliC and FliD are not (\~50% identity). We therefore focused on FliC and FliD for subsequent biochemical assays.

2.2. ETEC Flagellin Blocks TNF-Induced IκBα Degradation {#sec2dot2-pathogens-06-00018}
-------------------------------------------------------

To examine whether FliC and/or FliD protect HCT-8 cells from TNF-induced NF-κB activation, we generated ETEC H10407 *fliC* and *fliD* mutants and prepared cell-free supernatants from these mutant strains in RPMI 1640. ETEC Δ*fliC* supernatants failed to block TNF-induced IκBα degradation ([Figure 2](#pathogens-06-00018-f002){ref-type="fig"}A).

Complementing ETEC Δ*fliC* with a *fliC* expression plasmid partially restored the protective phenotype (*p* = 0.1; [Figure 2](#pathogens-06-00018-f002){ref-type="fig"}A). By contrast, the ETEC Δ*fliD* supernatant behaved more similarly to the WT ETEC supernatant, though these data did not reach statistical significance (*p* = 0.1; [Figure 2](#pathogens-06-00018-f002){ref-type="fig"}A). We therefore concluded that *fliC* expression was necessary for the ESF phenotype. We next determined whether recombinant FliC is sufficient to account for the ESF phenotype. We expressed ETEC FliC in *E. coli* BL21 (DE3) and purified the recombinant protein using Ni-NTA chromatography ([Figure 2](#pathogens-06-00018-f002){ref-type="fig"}B). FliC blocked IκBα degradation in response to TNF in a dose-dependent manner ([Figure 2](#pathogens-06-00018-f002){ref-type="fig"}C).

To eliminate the potential impact of LPS contamination, we also expressed and purified FliC from *E. coli* ClearColi 21 (DE3). The ClearColi strain incorporates seven genetic deletions that inhibit carbohydrate modifications of the LPS molecule. Recombinant proteins expressed from ClearColi BL21 (DE3) do not need removal of contaminating LPS to avoid TLR4 activation \[[@B15-pathogens-06-00018]\]. Pre-incubating HCT-8 cells with FliC purified from ClearColi also protected IκBα from TNF-induced degradation in a dose-dependent manner ([Figure 2](#pathogens-06-00018-f002){ref-type="fig"}D). The protective phenotype mediated by FliC was also heat-stable ([Figure 2](#pathogens-06-00018-f002){ref-type="fig"}E), consistent with previous data \[[@B14-pathogens-06-00018]\].

To determine whether the FliC-mediated phenotype was abrogated by blocking Toll-like receptor 5 (TLR5) recognition, we first treated HCT-8 cells with the TLR5 antagonist hTLR5-Fc, followed by FliC and TNF. IκBα degradation in response to TNF stimulation was still inhibited by ETEC FliC, even after hTLR5-Fc pre-incubation ([Figure 2](#pathogens-06-00018-f002){ref-type="fig"}F).

2.3. FliC Domain Mapping {#sec2dot3-pathogens-06-00018}
------------------------

The function of flagellin is broadly conserved among all flagellated bacteria. Nevertheless, outside the N- and C-terminal regions that comprise its intramolecular coiled-coil, the flagellin (FliC) protein itself exhibits localized sequence/structure variability between otherwise closely related bacteria. For example, whereas the central region of Salmonella FliC contains two distinct \~100 residue domains \[[@B16-pathogens-06-00018]\], sequence analyses suggest that ETEC FliC contains only a single, fused central domain consisting of residues 176--395. Importantly, residues within this central region of *E. coli* flagellin comprise variable H serotype-specific epitopes \[[@B6-pathogens-06-00018]\], suggesting that these sequences could impart strain-specific activities to the FliC protein.

To investigate if a specific FliC subdomain might account for the IκBα protective phenotype, we overexpressed and purified three truncated FliC proteins designated as FliC(1--395), FliC(176--395), and FliC(176--488) ([Figure 3](#pathogens-06-00018-f003){ref-type="fig"}A). These proteins were expressed from pT7HMT to facilitate removal of the N-terminal His-tag using TEV protease. While the presence of a His-tag did not affect the activity of full-length FliC in blocking IκBα degradation in response to TNF ([Figure 3](#pathogens-06-00018-f003){ref-type="fig"}B), none of the truncated FliC proteins were active. As a control, both tagged- and untagged-FliC were heat-stable, consistent with the heat-stability of the ESF we described previously ([Figure 3](#pathogens-06-00018-f003){ref-type="fig"}C, \[[@B14-pathogens-06-00018]\]).

2.4. Intracellular Expression of fliC Fails to Block IκBα Degradation in Response to TNFα {#sec2dot4-pathogens-06-00018}
-----------------------------------------------------------------------------------------

We next sought to determine whether mammalian expression of FliC would be sufficient to block TNF-induced IκBα degradation. We expressed FliC fragments from a mammalian cell expression vector and transfected these plasmids into HCT-8 cells ([Figure 4](#pathogens-06-00018-f004){ref-type="fig"}A). The expressed proteins were not toxic to HCT-8 cells ([Figure 4](#pathogens-06-00018-f004){ref-type="fig"}B), but they were unable to block TNF-induced IκBα degradation ([Figure 4](#pathogens-06-00018-f004){ref-type="fig"}C).

Here we identified ETEC FliC as necessary and sufficient to inhibit IκBα degradation in response to TNF stimulation ([Figure 1](#pathogens-06-00018-f001){ref-type="fig"} and [Figure 2](#pathogens-06-00018-f002){ref-type="fig"}). Surprisingly, blocking TLR5 recognition of flagellin did not eliminate this phenotype, suggesting a potential TLR5-independent mechanism of action ([Figure 2](#pathogens-06-00018-f002){ref-type="fig"}). We were unable to define the FliC subdomain responsible for this activity, despite truncating the protein into soluble fragments that comprised the variable central domain ([Figure 3](#pathogens-06-00018-f003){ref-type="fig"}). We also observed that endogenous expression of FliC in mammalian cells did not reconstitute this phenotype ([Figure 4](#pathogens-06-00018-f004){ref-type="fig"}), suggesting a potential extracellular target for FliC.

TNF-TNFR1-mediated NF-κB activation occurs on the cell surface and is associated with lipid rafts \[[@B17-pathogens-06-00018]\]. Cationic cell-penetrating peptides can disrupt TNF-mediated NF-κB signaling by inducing TNF receptor internalization in a clathrin-dependent manner \[[@B18-pathogens-06-00018]\].

The mechanism of FliC-mediated inhibition of IκBα degradation in response to TNF could be associated with TNFR internalization, as we had previously observed that blocking clathrin-dependent endocytosis affected the activity of the ETEC secreted factor (ESF; \[[@B14-pathogens-06-00018]\]). Future characterization of the phenotype we report here has the potential to provide insight to the development of anti-inflammatory compounds that target NF-κB, an approach that might prove efficacious in treating autoimmune disorders. These data also reinforce the notion that bacterial pathogens have evolved mechanisms to subvert the activation of host innate signaling pathways.

3. Materials and Methods {#sec3-pathogens-06-00018}
========================

3.1. Reagents and Antibodies {#sec3dot1-pathogens-06-00018}
----------------------------

Antibiotics were purchased from Fisher Scientific (Waltham, MA, USA). Restriction enzymes were purchased from New England BioLabs (Ipswich, MA, USA). TNFα was purchased from Cell Signaling Technology (Beverly, MA, USA). hTLR5-Fc was purchased from InvivoGen (San Diego, CA, USA). Antibodies were purchased from the following sources: HA, FLAG, and c-Myc (Sigma, St. Louis, MO, USA), His and tubulin (Santa Cruz, Dallas, TX, USA), IκBα (Cell Signaling Technology).

3.2. Bacterial Strains and Plasmids {#sec3dot2-pathogens-06-00018}
-----------------------------------

Bacterial strains and plasmids are described in [Table 2](#pathogens-06-00018-t002){ref-type="table"}. ETEC mutants were derived from wild-type ETEC H10407 \[[@B19-pathogens-06-00018]\]. *E. coli* DH5α was used for routine molecular biological manipulations while *E. coli* BL21 (DE3) and ClearColi BL21 (DE3) were used for protein expression. Plasmids pKD3 and pKD46 were used to construct ETEC H10407 mutants. Plasmids pET28a and pT7HMT \[[@B20-pathogens-06-00018]\] were used to express recombinant proteins. All bacterial strains were grown aerobically in Luria-Bertani (LB) broth or on LB plates with antibiotics at 37 °C.

3.3. Cell Lines and Culture Conditions {#sec3dot3-pathogens-06-00018}
--------------------------------------

The intestinal epithelial cell line HCT-8 was maintained at 37 °C, 5% CO~2~ in RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS) and penicillin-streptomycin (100 U/mL). HCT-8 cells were seeded in 6-well plates at a concentration of 5 × 10^5^ cells/well. Media was replaced with fresh RPMI 1640 lacking both FBS and penicillin-streptomycin prior to experimentation.

3.4. ETEC Supernatant {#sec3dot4-pathogens-06-00018}
---------------------

ETEC H10407 culture supernatants were prepared in either RPMI 1640 or in M9 minimal medium (M9 salts, 2 mM MgSO~4~, 0.1 mM CaCl~2~, 0.4% glucose). Cell-free supernatants were concentrated by using Centricon Plus-70 Centrifugal Filters (EMD Millipore, Billerica, MA, USA) with a membrane Normal Molecular Weight Limit (NMWL) of 3 kDa and then precipitated using acetone. Protein pellets were collected by centrifugation at 15,000× *g*, 4 °C for 10 min, and resuspended in 0.15 M NaCl for fast protein liquid chromatography analysis.

3.5. Fast Protein Liquid Chromatography and Mass Spectrometry {#sec3dot5-pathogens-06-00018}
-------------------------------------------------------------

ETEC H10407 supernatants were fractionated using a AKTA Fast Protein Liquid Chromatography (FPLC) system (GE Life Sciences, Marlborough, MA, USA) to facilitate molecular characterization of the ESF. Acetone-precipitated supernatants from M9-grown ETEC cultures were resuspended in 10 mL 0.15 M NaCl, clarified by 0.22 µm filtration, and applied at 4 mL/min to a Superdex S200 26/60 column (GE Life Sciences) that had previously been equilibrated in 20 mM Tris (pH 8.0), 200 mM NaCl. The ESF-containing eluent was collected from the column between 110--130 mL, and dialyzed against 4 L of 20 mM Tris (pH 8.0) in preparation for further chromatography. The ESF-containing sample was applied to a 1 mL Resource Q anion exchange column (GE Life Sciences). The column was washed with 20 mM Tris (pH 8.0) until the OD~280~ value reach baseline, and then the bound proteins were eluted with a gradient to 1 M NaCl in the same buffer. Fractions of 1 mL were collected and then screened for their ability to prevent IκBα degradation in response to TNF, separated by SDS-PAGE, and detected using Silver Staining (Thermo Scientific, Waltham, MA, USA). Proteins from active fractions were excised and digested in-gel with trypsin (Promega, Madison, WI, USA). Proteins were identified using mass spectrometry at the Mass Spectrometry & Analytical Proteomics Laboratory, University of Kansas.

3.6. Construction of ETEC H10407 Mutants {#sec3dot6-pathogens-06-00018}
----------------------------------------

ETEC were generated using the Lambda Red Recombinase system \[[@B22-pathogens-06-00018]\]. PCR products containing chloramphenicol resistance cassettes were amplified from plasmid pKD3 using primers ([Table 3](#pathogens-06-00018-t003){ref-type="table"}) flanked with homologous upstream and downstream gene sequences. PCR products were transformed into ETEC H10407 carrying the pKD46 plasmid via electroporation. Potential mutants were screened on LB plates containing chloramphenicol. All mutants were confirmed using DNA sequencing. ETEC H10407 *fliC* was also expressed from pFLAG-CTC for complementation studies.

3.7. Recombinant Protein Expression and Purification {#sec3dot7-pathogens-06-00018}
----------------------------------------------------

Recombinant protein expression was induced with 1 mM IPTG, at 37 °C for 5 h. Recombinant proteins were purified by using nickel-affinity chromatography and subsequently dialyzed into PBS. Purified proteins were analyzed on 12% SDS-PAGE and concentrations were quantified using the Bradford method.

3.8. Transfection {#sec3dot8-pathogens-06-00018}
-----------------

HCT-8 cells were seeded in 6-well plates at a concentration of 2 × 10^5^ cells/well, grown to 70--80% confluence, and transfected with 2.5 µg plasmid DNA using Lipofectamine 3000 (Life Technology, Carlsbad, CA, USA). Transfected cells were stimulated with TNFα (20 ng/mL) at 12--48 h post-transfection.

3.9. Immunoblotting {#sec3dot9-pathogens-06-00018}
-------------------

HCT-8 cell pellets were resuspended in 10.0 mM HEPES, 1.5 mM MgCl~2~, 10.0 mM KCl, 0.5 mM DTT, 0.05% NP-40 containing protease inhibitor cocktails (Thermo Scientific) and incubated on ice for 30 min. Lysates were centrifuged (10,000× *g*, 4 °C, 10 min) and the supernatant was collected. Immunoblotting was carried out as previously described \[[@B14-pathogens-06-00018]\] by separating proteins using 10% SDS-PAGE and then transferring the proteins to nitrocellulose membranes. Membranes were blocked in Odyssey blocking buffer (Li-Cor, Lincoln, NE, USA) at room temperature for 1 h, and then incubated with appropriate primary and secondary primary antibodies. Immunoblots were developed using the Odyssey infrared imaging system (Li-Cor). Tubulin abundance was used to normalize IκBα abundance.

3.10. Statistical Analysis {#sec3dot10-pathogens-06-00018}
--------------------------

For all quantitative data, tubulin immunoblotting was used to normalize IκBα abundance. The data represent at least 3 independent experiments and were analyzed using one-way ANOVA with the Dunnett's multiple comparisons test. Asterisks indicate significantly different IκBα abundance as compared with the 'TNF only' lane. Statistical differences were evaluated using one-way ANOVA with the Dunnett's multiple comparisons test. *p*-values \< 0.05 were considered significant.
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![ESF fractionation and identification. (**A**) IκBα immunoreactivity after incubating HCT-8 cells with ETEC H10407-M9 supernatant (0.1--10 µg protein) and then stimulating the cells with TNF (20 ng/mL, 20 min) Asterisks indicate significantly different IκBα abundance as compared with the 'TNF only' lane; (**B**) IκBα immunoreactivity after incubating HCT-8 cells with ETEC H10407-M9 supernatant (0.1--10 µg protein) and then stimulating the cells with TNF (20 ng/mL, 20 min); (**C**) IκBα immunoreactivity after incubating HCT-8 cells with ETEC H10407-RPMI1640 and ETEC H10407-M9 supernatants (10 µg protein) without TNF; (**D**) IκBα immunoreactivity after incubating HCT-8 cells with ETEC H10407-M9 supernatant FPLC fractions for 1.5 h and then stimulating the cells with TNF (20 ng/mL, 20 min); (**E**) Sliver staining of FPLC fractions E and F on 10% SDS-PAGE.](pathogens-06-00018-g001){#pathogens-06-00018-f001}

![ETEC FliC blocks TNF-induced IκBα degradation. (**A**) IκBα immunoreactivity after incubating HCT-8 cells with WT and mutant ETEC supernatants (10 µg protein) and then stimulating the cells with TNF (20 ng/mL, 20 min); (**B**) Purified recombinant FliC resolved using 10% SDS-PAGE and Coomassie blue staining; (**C**) IκBα immunoreactivity after incubating HCT-8 cells with FliC-pET28a-BL21 (100 pg--10 µg) for 1.5 h followed by TNF stimulation (20 ng/mL, 20 min); (**D**) IκBα immunoreactivity after incubating HCT-8 cells with FliC-pET28a-ClearColi (100 pg--10 µg) for 1.5 h and then stimulating the cells with TNF (20 ng/mL, 20 min); (**E**) IκBα immunoreactivity after incubating HCT-8 cells with heated (100 °C, 20 min), recombinant FliC (1 µg) for 1.5 h followed by TNF stimulation (20 ng/mL, 20 min); (**F**) IκBα immunoreactivity after pretreating HCT-8 cells with 1.5 µg/mL hTRL5-Fc for 1 h, followed by FliC (100 ng/mL, 90 min) and TNF (20 ng/mL, 20 min).](pathogens-06-00018-g002){#pathogens-06-00018-f002}

![FliC truncations are inactive. (**A**) Purified FliC truncations +/− TEV protease treatment were resolved using 10% SDS-PAGE and analyzed by Coomassie blue staining (top) and Western blotting (bottom); (**B**) IκBα immunoreactivity after incubating HCT-8 cells with FliC truncations (1 µg) for 1.5 h followed by TNF stimulation (20 ng/mL, 20 min); (**C**) IκBα immunoreactivity after incubating HCT-8 cells with heated (100 °C, 20 min) FliC (1 µg) followed by TNF stimulation (20 ng/mL, 20 min).](pathogens-06-00018-g003){#pathogens-06-00018-f003}

![Intracellular expression of *fliC* fails to block IκBα degradation in response to TNFα. (**A**) Immunoreactivity of transfected FliC truncations expressed in HCT-8 cells 24 h post-transfection; (**B**) IκBα immunoreactivity in HCT-8 cells 24 h post-transfection of *fliC* truncations in the absence of TNF stimulation; (**C**) IκBα immunoreactivity in HCT-8 cells 24 h post-transfection of *fliC* truncations after TNF stimulation (20 ng/mL, 20 min).](pathogens-06-00018-g004){#pathogens-06-00018-f004}

pathogens-06-00018-t001_Table 1

###### 

Mass spectrometry results.

  Protein Candidates                           Sequence Coverage   Identity to *E. coli* MG1655   GenBank Accession \#
  -------------------------------------------- ------------------- ------------------------------ ----------------------
  Major outer membrane lipoprotein             49% over 78 AAs     100%                           CBJ00536.1
  Outer membrane protein A                     26% over 346 AAs    99%                            CBJ01214.1
  Flagellar hook-associated protein 2 (FliD)   44% over 470 AAs    50%                            CBJ01536.1
  Flagellin (FliC)                             71% over 487 AAs    52%                            CBJ01535.1

pathogens-06-00018-t002_Table 2

###### 

Strains and plasmids used in this study.

  Strain or Plasmid         Description                                      Source or Reference
  ------------------------- ------------------------------------------------ -------------------------------
  *Strains*                                                                  
  ETEC H10407               O78:H11, CFA/I, LT^+^ and ST^+^                  \[[@B19-pathogens-06-00018]\]
  *E. coli* DH5α            Cloning strain                                   New England BioLabs
  *E. coli* BL21 (DE3)      Protein overexpression strain                    Novagen
  ClearColi BL21 (DE3)      Protein overexpression                           Lucigen
  ETEC Δ*fliC*              ETEC H10407 *fliC* mutant                        This study
  ETEC Δ*fliD*              ETEC H10407 *fliD* mutant                        This study
  ETEC Δ*fliC*/pFliC-FLAG   ETEC H10407 Δ*fliC* complemented with *fliC*     This study
  *Plasmids*                                                                 
  pFLAG-CTC                 FLAG-tagged protein expression                   Sigma
  pET28a                    His~6~ fusion protein expression                 Novagen
  pT7HMT                    His~6~ fusion protein expression with TEV site   \[[@B20-pathogens-06-00018]\]
  pKD3                      Template for mutagenic PCR products              \[[@B21-pathogens-06-00018]\]
  PKD46                     Lambda Red mediated mutagenesis                  \[[@B21-pathogens-06-00018]\]
  pCMV                      Mammalian expression vector with HA-tag          \[[@B22-pathogens-06-00018]\]
  pET28a-FliC               FliC in pET28a                                   This study
  pT7HMT-FliC               FliC in pT7HMT                                   This study
  pT7HMT-FliC (176--395)    FliC (176--395) in pT7HMT                        This study
  pT7HMT-FliC (1--395)      FliC (1--395) in pT7HMT                          This study
  pT7HMT-FliC (176--488)    FliC (176--488) in pT7HMT                        This study
  pCMV-FliC (1--487)        FliC (1--487) in pCMV                            This study
  pCMV-FliC (176--395)      FliC (176--395) in pCMV                          This study
  pCMV-FliC (1--395)        FliC (1--395) in pCMV                            This study
  pCMV-FliC (176--487)      FliC (176--487) in pCMV                          This study
  pCMV-FliC (2--395)        FliC (2--395) in pCMV                            This study
  pCMV-FliC (2--487)        FliC (2--487) in pCMV                            This study

pathogens-06-00018-t003_Table 3

###### 

Oligonucleotides used in this study.

  Primer                                                  Purpose                             Sequence (5′-3′)
  ------------------------------------------------------- ----------------------------------- -------------------------------------------------------
  PRH-3427                                                Delete ETEC H10407 *fliD*           A~2~T~2~GC~2~GATA~2~C~3~GCT~2~ATCTACTGT~3~GCA~2~TC
  A~4~G~2~A~2~T~2~AG~2~TGTGTA2CTG~2~AGCTGCT~2~C                                               
  PRH-3428                                                Delete ETEC H10407 *fliD*           T~2~GTGCATAG~2~CT~4~GAGC~2~GCTCGCG~2~TATAC
  ATGCTGAC~2~TC~2~GTGA~2~TG~3~A~2~T~2~AGC~2~ATG~2~TC~2~                                       
  PRH-3429                                                Verify *fliD* deletion              TCTCTC~2~TGT~6~CT~2~A~2~CG~2~CT
  PRH-3430                                                Verify *fliD* deletion              GCTGAT~2~GT~2~GTC~2~TGCATA~3~CA
  PRH-3431                                                Delete ETEC H10407 *fliC*           CGTG~3~CA~2~CAGC~3~A~2~TA~2~CATCA~2~GT~2~GTA~2~T~2~GA
  TA~2~G~2~A~4~GATCGTGTAG~2~CTG~2~AGCTGCT~2~C                                                 
  PRH-3432                                                Delete ETEC H10407 *fliC*           GCG~3~CAGA~6~C~4~GC~2~G~2~TG2CG~5~T~2~GAGCGA
  TA~2~GTGTA~4~TG~3~A~2~T~2~AGC~2~ATG~2~TC~2~                                                 
  PRH-3433                                                Verify *fliC* deletion              ATGATGCGCAGAGTAGAGT~2~GTAT
  PRH-3434                                                Verify *fliC* deletion              ATGAT~2~ATC~2~GT~3~CTGCAG~3~T~2~
  PRH-3619                                                Clone *fliC* pCMV-XhoI              TAC~2~GCTCGAGATG~2~CACA~2~GTCAT~2~A~2~TA
  PRH-3620                                                Clone *fliC* pCMV-NotI              ATA~2~GA~2~TGCG~2~C~2~GCACGCAGCAGAGACAGTA
  PRH-3681                                                Clone *fliC* pET28a-Nde I           GGA~2~T~2~C~2~ATATG~2~CACA~2~GTCAT~2~A~2~TACA
  PRH-3682                                                Clone *fliC* pET28a-XhoI            TAC~2~GCTCGAGACGCAGCAGAGACAGTA
  PRH-3684                                                Clone *fliC* pFLAG-CTC-XhoI         TAC~2~GCTCGAG~2~CACA~2~GTCAT~2~A~2~TA
  PRH-3685                                                Clone *fliC* pFLAG-CTC-BglII        G~2~A~2~GATCTACGCAGCAGAGACAGTA
  PRH-3788                                                Clone *fliC* 176-395 pCMV-XhoI      TATAT~2~ACTCGAG~2~ATG~2~CGCGCAGA~3~GCA~2~
  PRH-3789                                                Clone *fliC* 176-395 pCMV-NotI      ATA~2~GA~2~TGCG~2~C~2~GCT~2~GCA~2~CGAT~4~
  PRH-3543                                                Clone *fliC* pT7HMT-BamHI           TACGCG~2~ATC~2~ATG~2~CACA~2~GTCAT~2~A~2~TACA~2~
  PRH-3844                                                Clone *fliC* pT7HMT-NotI            ATA~2~GAT~2~GCG~2~C~2~GCT~2~A~2~CGCAGCAGAGA
  PRH-3845                                                Clone *fliC* 176-395 pT7HMT-BamHI   TACGCG~2~ATC~2~GATG~2~CGCGCAGA~3~
  PRH-3851                                                Clone *fliC* 176-395 pT7HMT-NotI    ATA~2~GAT~2~GCGGC~2~GCTCAT~2~GCA~2~CGAT~4~
  PRH-3971                                                Clone *fliC* pCMV-XhoI              TAC~2~GCTCGAG~2~CACA~2~GTCAT~2~A~2~TACA~3~CAGC~2~
